Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

Core Insights - Fate Therapeutics, Inc. has appointed Matthew Abernethy to its Board of Directors, effective May 29, 2025, while Timothy P. Coughlin has stepped down from the Board [1][2] Company Overview - Fate Therapeutics is a clinical-stage biopharmaceutical company focused on developing induced pluripotent stem cell (iPSC)-derived cellular immunotherapies [4] - The company aims to create a pipeline of off-the-shelf cell therapy products targeting autoimmunity and oncology [4] Leadership Changes - Matthew Abernethy brings over 15 years of experience in corporate finance and investor relations within the biotech and medical device sectors [1][2] - Abernethy has served as Chief Financial Officer at Neurocrine Biosciences since November 2017 and has held various finance roles at Zimmer Biomet Holdings [2][3] Strategic Focus - Abernethy emphasizes the potential of cell therapy to aid patients with cancer and immunological disorders, particularly highlighting the product FT819 for autoimmune diseases like lupus [2]